San Diego-based Ligand Pharmaceuticals is acquiring San Diego-based Pfenex for a total deal transaction of up to $516 million.
Numerous major global biopharma companies reported first-quarter 2020 earnings. Typically, the COVID-19 pandemic has affected the companies, although not necessarily in a straightforward way. Many of the companies reported increased sales for the quarter as customers increased stockpiles and inventory in preparation for the pandemic, while other forms of sales and clinical trials were negatively impacted. Here’s a look.
The European Commission approved Pfizer Inc.’s Ruxience (rituximab) – a monoclonal antibody and biosimilar to MabThera – for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.
Merck is spinning off products from the company’s Women’s Health, Legacy Brands and Biosimilars businesses.
China’s Innovent Biologics forged a licensing agreement with biosimilar-focused Coherus BioSciences to commercialize Innovent’s biosimilar candidate to Avastin (bevacizumab) in the United States and Canada.
The U.S. Food and Drug Administration approved Amgen Inc.’s biosimilar copy of Johnson & Johnson’s blockbuster rheumatoid arthritis (RA) drug Remicade.
China’s Bio-Thera Solutions Ltd. won a regulatory approval for the company’s version of AbbVie Inc.’s blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world’s second-largest drug market.
Novartis won FDA approval for a long-delayed version of Amgen’s $4 billion seller Neulasta drug, helping the Swiss drugmaker in an uphill battle to sell copies of rivals’ blockbusters in the U.S.
India’s ability to produce affordable generic drugs has led to the country’s reputation of being the “pharmacy of the world,” according to Dr. Reddy’s Vice President Radha Iyer.
A new study conducted by the Pacific Research Institute (PRI) found that wider adoption of biosimilars in the United States would create significant savings to state Medicaid programs and consumers with commercial insurance.